Cor Vasa 2019, 61(1):20-27 | DOI: 10.1016/j.crvasa.2018.05.002

The changes in achievement of target LDL-cholesterol levels between 2006 and 2017 in Czech patients with chronic coronary heart disease

Pavla Vorlíčková^a, Otto Mayer Jr.^a,b, Jan Bruthans^a,c, Jitka Seidlerová^a,b, Julius Gelžinský^a,b, Markéta Mateřánková^a,b, Martina Cvíčela^a,d, Renata Cífková^c,d, Jan Filipovský^a,b

^a II. interní klinika, Lékařská fakulta v Plzni, Univerzita Karlova a Fakultní nemocnice Plzeň, Plzeň

^b Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova

^c Centrum kardiovaskulární prevence, 1. lékařská fakulta Univerzity Karlovy a Thomayerova nemocnice, Praha

^d Kardiologická klinika, Fakultní nemocnice Plzeň, Plzeň

Several clinical trials have shown that patients with coronary heart disease (CHD) benefit from more aggressive treatment to achieve lower target LDL cholesterol. We aimed to analyze the changes in achievement of guideline recommended LDL target during last 10 years and the usual dosage of statin in secondary prevention of CHD. We analyzed 1349 patients (21.7% females) aged 64.9 years (standard deviation [SD] ± 9.0) after acute coronary syndrome and/or coronary revascularization from three different cohorts (Czech samples of EUROASPIRE III, IV and V). Overall control of hypercholesterolemia substantially improved from year 2006 to year 2017, 52% of CHD patients did not achieve the guideline target LDL In conclusion, although majority of CHD patients are currently being treated with statin, the usual doses and adherence to the recommended target remains unsatisfactory. Maximal statin up-titration and namely more frequent use of combination of hypolipidemic drugs may substantially improve this situation.

Keywords: Dosage, EUROASPIRE, Secondary prevention, Statin, Treatment target adherence

Published: March 21, 2019  Show citation